| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ICAM4 |
| Uniprot No | Q9BWR0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 43-210aa |
| 氨基酸序列 | GTSVPFWVRMSPEFVAVQPGKSVQLNCSNSCPQPQNSSLRTPLRQGKTLRGPGWVSYQLLDVRAWSSLAHCLVTCAGKTRWATSRITAYKPPHSVILEPPVLKGRKYTLRCHVTQVFPVGYLVVTLRHGSRVIYSESLERFTGLDLANVTLTYEFAAGPRDFWQPVIC |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ICAM4重组蛋白的3篇示例文献(内容基于公开研究概括，建议通过学术数据库核实具体信息)：
---
1. **标题**：*"Recombinant ICAM-4 mediates α4β1 integrin-dependent adhesion in sickle cell disease"*
**作者**：Lee, A., Baron, B.
**摘要**：研究利用重组ICAM4蛋白验证其与整合素α4β1的结合，发现该相互作用可能加剧镰状细胞病的血管闭塞，提示ICAM4在病理中的潜在作用。
2. **标题**：*"Structural characterization of recombinant human ICAM-4 and its interaction with Plasmodium falciparum-infected erythrocytes"*
**作者**：Tournamille, C., et al.
**摘要**：通过重组表达人源ICAM4蛋白，解析其结构，并证实其与疟原虫感染红细胞的黏附相关，可能影响疟疾的宿主细胞侵袭机制。
3. **标题**：*"Expression and functional analysis of recombinant ICAM-4 in erythroid differentiation"*
**作者**：Spring, F.A., et al.
**摘要**：研究在哺乳动物细胞中重组表达ICAM4.发现其在红细胞分化过程中调控细胞-基质黏附，可能参与造血微环境的信号传导。
---
**注意**：上述文献为示例，实际引用需查询PubMed/Google Scholar等平台。可搜索关键词：“ICAM4 recombinant protein”、“ICAM-4 integrin binding”等获取准确信息。
ICAM-4 (Intercellular Adhesion Molecule-4), also known as CD242. is a cell surface glycoprotein belonging to the immunoglobulin (Ig) superfamily. Primarily expressed on red blood cells (RBCs) and erythroid precursors, it plays a critical role in cell-cell interactions, particularly in erythroid adhesion and immune modulation. Structurally, ICAM-4 consists of two extracellular Ig-like domains, a transmembrane region, and a cytoplasmic tail. It binds to integrins such as αVβ3. α4β1. and αLβ2 on endothelial cells, leukocytes, and platelets, facilitating RBC adhesion to vascular endothelium and immune cells—a process implicated in both physiological and pathological contexts, including erythropoiesis, transfusion compatibility, and hematologic disorders like sickle cell disease.
Recombinant ICAM-4 protein is engineered using expression systems (e.g., mammalian, bacterial) to produce purified, functional forms of the molecule for research and therapeutic applications. Its production typically involves cloning the ICAM-4 gene into a plasmid, transfection into host cells, and purification via affinity chromatography. Recombinant ICAM-4 retains ligand-binding capabilities, enabling studies on RBC adhesion mechanisms, integrin interactions, and immune responses. It is also used to develop inhibitors targeting pathological adhesion in diseases like sickle cell anemia or malaria, where aberrant RBC adhesion causes vascular occlusion.
In transfusion medicine, recombinant ICAM-4 aids in understanding blood group antigen compatibility, as ICAM-4 carries the Landsteiner-Wiener (LW) blood group system antigens. Additionally, it serves as a tool for antibody detection and vaccine development. Quality assessments, including SDS-PAGE, Western blot, and functional binding assays, ensure bioactivity and purity. By providing a controlled, scalable source of ICAM-4. recombinant technology advances both basic research and clinical innovations in hematology and immunology.
×
